Published in J Nucl Med on February 01, 2005
Radioimmunotherapy of Non-Hodgkin's lymphoma. J Nucl Med (2004) 2.06
Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm (2010) 3.23
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 2.79
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
A novel method of 18F radiolabeling for PET. J Nucl Med (2009) 2.35
Renal dosimetry: ready for biological effective dose? Cancer Biother Radiopharm (2010) 2.24
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res (2007) 2.06
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 2.05
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 1.83
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood (2013) 1.78
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 1.77
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem (2010) 1.76
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood (2009) 1.72
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med (2005) 1.69
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood (2012) 1.63
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) (2013) 1.58
Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57
Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res (2005) 1.56
CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res (2007) 1.51
Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin (2006) 1.50
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A (2006) 1.50
Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49
Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med (2005) 1.49
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res (2005) 1.49
IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A (2007) 1.47
A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med (2010) 1.47
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol (2005) 1.45
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood (2004) 1.41
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol (2006) 1.35
Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer (2007) 1.35
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2007) 1.35
Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res (2002) 1.35
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.34
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol (2009) 1.34
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging (2002) 1.31
Pretargeted molecular imaging and radioimmunotherapy. Theranostics (2012) 1.31
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther (2006) 1.30
CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res (2004) 1.25
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2006) 1.23
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res (2005) 1.22
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med (2006) 1.18
High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem (2011) 1.17
Sphingolipid targets in cancer therapy. Mol Cancer Ther (2006) 1.17
Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2010) 1.17
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res (2004) 1.16
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1.15
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res (2008) 1.15
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther (2010) 1.13
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.12
Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res (2003) 1.12
177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nucl Med Biol (2005) 1.12
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) (2013) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat (2004) 1.10
The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res (2007) 1.10
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood (2011) 1.10
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res (2005) 1.09
Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 1.09
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res (2008) 1.08
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol (2010) 1.08
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res (2008) 1.07
A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res (2003) 1.05
Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res (2011) 1.05
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (2012) 1.05
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology (2008) 1.04
Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res (2003) 1.03
TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol (2010) 1.03
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother (2004) 1.02
Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest (2006) 1.02
Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol (2007) 1.02
Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res (2008) 1.01
Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem (2008) 1.01
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J Nucl Med (2011) 1.00
Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res (2003) 1.00
New lyophilized kit for rapid radiofluorination of peptides. Bioconjug Chem (2012) 1.00
Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging (2003) 0.99
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica (2010) 0.99
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood (2009) 0.99